Clarus Ventures and Aisling Capital jumped on an opportunity to return money to investors through potential royalties for cancer compound ibrutinib, but the firms don't plan to make a habit of investing in royalty streams.

The firms paid just under $97 million last week to acquire a 20% stake of Royalty Pharma's royalty stream for the Bruton's tyrosine kinase (Btk) inhibitor.